Vaccine DCs present tumor-lysate MHC II peptides to activate TH1 cells, which provide help for tumor-specific CD8+ CTLs. These CTLs recognize corresponding antigens on tumor cells (via MHC I) and kill them via perforin/granzyme and Fas–FasL pathways; the vaccine does not directly kill target-expressing cells.